©2026 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy

Contributor:

First Impressions of DORC EVA System and Customer Service
First Impressions of DORC EVA System and Customer Service

David Miller, MD

St<strike>ep</strike>upid Edits in a Neovascular AMD Patient
Stepupid Edits in a Neovascular AMD Patient

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History
Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD
Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies
Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague
Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment
Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Wet AMD and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

DME, DR, and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD